Metastasis to the parotid region as an initial presentation of renal cell carcinoma: A case report

Yanlan,Chai; Liping,Song; Shaomin,Che; Zi,Liu

doi:10.3892/ol.2013.1110

Metastasis to the parotid region as an initial presentation of renal cell carcinoma: A case report

Authors:
- Chai Yanlan
- Song Liping
- Che Shaomin
- Liu Zi
View Affiliations

Affiliations: Cancer Center, First Hospital of Xi'an Jiaotong University, Shaan'xi, Xi'an 710061, P.R. China
Published online on: January 7, 2013 https://doi.org/10.3892/ol.2013.1110
Pages: 997-999

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Distant metastasis of renal cell carcinoma (RCC) to the parotid region is extremely rare, particularly as an initial presentation. In the present study, we report a rare case of parotid region metastasis from RCC as an initial presentation in a 44-year‑old female who presented with a painless lump in the right parotid region. Investigation revealed RCC in the left renal region and metastasis to the right iliac area. A radical nephrectomy was performed but the patient refused any further treatment. After seven months, the patient reappeared with systemic multiple metastases, with the exception of previous metastases that were enlarging significantly. On admission, interleukin-2 and local radiotherapy were administered. However, oral mucositis occurred. Targeted therapy with sunitinib was recommended.

View Figures

View References

1	Vara A, Madrigal B, Pérez del Río MJ, et al: Parotid metastasis from renal clear cell adenocarcinoma. An unusual site for metastasis. Urol Int. 61:196–198. 1998. View Article : Google Scholar : PubMed/NCBI
2	Pisani P, Angeli G, Krangli M and Pia F: Renal carcinoma metastasis to the parotid gland. J Laryngol Otol. 104:352–354. 1990. View Article : Google Scholar : PubMed/NCBI
3	Leibovich BC, Pantuck AJ, Bui MH, et al: Current staging of renal cell carcinoma. Urol Clin North Am. 30:481–497. 2003. View Article : Google Scholar : PubMed/NCBI
4	Karumanchi SA, Merchan J and Sukhatme VP: Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens. 11:37–42. 2002. View Article : Google Scholar : PubMed/NCBI
5	Suh JH, Oak T, Ro JY, et al: Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renalcell carcinoma in older patients. Int J Clin Exp Pathol. 2:489–493. 2009.PubMed/NCBI
6	Mena AC, Pulido EG and Guillén-Ponce C: Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: Sunitinib. Anticancer Drugs. 21(Suppl 1): S3–S11. 2010. View Article : Google Scholar : PubMed/NCBI
7	Miah MS, White SJ, Oommen G, et al: Late simultaneous metastasis of renal cell carcinoma to the submandibular and thyroid gland seven years after radical nephrectomy. Int J Otolaryngol. 2010:6980142010.PubMed/NCBI
8	Bianchi M, Sun M, Jeldres C, et al: Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol Ann Oncol. 23:973–980. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sarkis P, Bou-Malhab F and Mouaccadieh L: Solitary laryngeal metastasis from clear cell carcinoma of the kidney: Clinical case and review of the literature. Prog Urol. 22:307–309. 2012.(In French).
10	Oudard S, George D, Medioni J and Motzer R: Treatment options in renal cell carcinoma: past, present and future. Ann Oncol. 18(Supl 10): x25–x31. 2007. View Article : Google Scholar : PubMed/NCBI
11	Matrana MR, Atkinson B, Jonasch E and Tannir NM: Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol. 6:189–198. 2011. View Article : Google Scholar : PubMed/NCBI
12	Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients withmetastatic renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
13	Escudier B, Bellmunt J, Négrier S, et al: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) plus interferon-alpha 2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts). 27(Suppl): 15S2009.
14	Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
15	Hudes G, Carducci M, Tomczak P, et al: Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar
16	Escudier B: Sorafenib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther. 11:825–836. 2011. View Article : Google Scholar : PubMed/NCBI
17	Motzer RJ, Escudier B, Oudard S, et al RECORD 1 Study Group: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer. 116:4256–4265. 2010. View Article : Google Scholar : PubMed/NCBI
18	National Comprehensive Cancer Network: NCCN Clinical Practice Guide-lines in Oncology™. Kidney Cancer. V.2.2010. Available at http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf, accessed March 26, 2010.
19	Hutson TE: Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist. 16(Suppl 2): 14–22. 2011. View Article : Google Scholar : PubMed/NCBI
20	Mizuno R and Oya M: Biomarkers of response to molecular targeted therapy in renal cell carcinoma. Gan To Kagaku Ryoho. 38:1088–1091. 2011.(In Japanese).
21	Eisengart LJ, MacVicar GR and Yang XJ: Predictors of response to targeted therapy in renal cell carcinoma. Arch Pathol Lab Med. 136:490–495. 2012. View Article : Google Scholar : PubMed/NCBI